Brief: Provectus Biopharmaceuticals Initiates Preclinical Study Of Oral Pv-10
29/09/2025 13:10
Sept 29 (Reuters) - Provectus Biopharmaceuticals Inc PVCT.PK: PROVECTUS BIOPHARMACEUTICALS INITIATES PRECLINICAL STUDY OF ORAL PV-10 IN BLADDER CANCER Source text: ID:nGNX1GDwmc Further company coverage: PVCT.PK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Provectus Biopharmaceuticals
See all newsBrief: Provectus Biopharmaceuticals Reports Oral Pv-10 Anti-Tumor Activity In Preclinical Bladder Cancer Study
Brief: Provectus Biopharmaceuticals Initiates Preclinical Study Of Oral Pv-10
RCS - VisiRose - VisiRose Introduces Therapy for Eye Infections
RCS - FINOS - FINOS Welcomes Seven Financial Leaders
Brief: Provectus Biopharmaceuticals Announces Poster Presentation of Rose Bengal Sodium for Treatment of Full-Thickness Cutaneous Wounds at SID 2024 Annual Meeting